Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Ryoichi Narita"'
Autor:
Atsuhiro Morita, Nobuharu Tamaki, Haruhiko Kobashi, Nami Mori, Keiji Tsuji, Shintaro Takaki, Chitomi Hasebe, Takehiro Akahane, Hironori Ochi, Toshie Mashiba, Naohito Urawa, Hideki Fujii, Akeri Mitsuda, Masahiko Kondo, Chikara Ogawa, Yasushi Uchida, Ryoichi Narita, Hiroyuki Marusawa, Yoshihito Kubotsu, Tomomichi Matsushita, Masaya Shigeno, Hideo Yoshida, Katsuaki Tanaka, Eisuke Okamoto, Toyotaka Kasai, Toru Ishii, Kazuhiko Okada, Masayuki Kurosaki, Namiki Izumi
Publikováno v:
JGH Open, Vol 8, Iss 4, Pp n/a-n/a (2024)
Abstract Background and aim In patients with chronic hepatitis C, 8 weeks of glecaprevir and pibrentasvir (GLE/PIB) treatment for chronic hepatitis (non‐cirrhosis) and 12 weeks for cirrhosis have been approved in Japan. However, whether 8 weeks of
Externí odkaz:
https://doaj.org/article/0d9873a1fd55472ea90b8aee2ad5fcad
Autor:
Tetsuya Ishida, Hideyasu Nagamatsu, Tetsuya Ueo, Ryoichi Narita, Ken Takahashi, Masaki Urabe, Yuka Yanai, Kazumi Togo
Publikováno v:
Case Reports in Gastroenterology, Vol 8, Iss 1, Pp 44-50 (2014)
We report a 45-year-old female patient who developed acute hepatic disorder during anti-tumor necrosis factor α therapy for the treatment of Crohn's disease (CD). She was diagnosed as colonic CD and placed on infliximab (IFX). She was negative for h
Externí odkaz:
https://doaj.org/article/05eae3b885af4c5a8b9f531d31b8a9c2
Publikováno v:
Gastroenterology Insights, Vol 1, Iss 1, Pp e8-e8 (2009)
A rare case of Brunner’s gland hyperplasia mimicking duodenal cancer is reported. A 68-year old woman had an elevated lesion in the second portion of the duodenum. Endoscopy after spraying with indigo carmine dye showed a granular appearance and fo
Externí odkaz:
https://doaj.org/article/afe320dd474e4a27a407b76389273d17
Autor:
Shintaro Takaki, Masayuki Kurosaki, Nami Mori, Keiji Tsuji, Hironori Ochi, Hiroyuki Marusawa, Shinichiro Nakamura, Toshifumi Tada, Ryoichi Narita, Yasushi Uchida, Takehiro Akahane, Masahiko Kondo, Atsunori Kusakabe, Koichiro Furuta, Haruhiko Kobashi, Hirotaka Arai, Michiko Nonogi, Takashi Tamada, Chitomi Hasebe, Chikara Ogawa, Takashi Sato, Nobuharu Tamaki, Yutaka Yasui, Kaoru Tsuchiya, Namiki Izumi
Publikováno v:
Investigational New Drugs. 41:340-349
Autor:
Hironori Ochi, Masayuki Kurosaki, Kouji Joko, Toshie Mashiba, Nobuharu Tamaki, Kaoru Tsuchiya, Hiroyuki Marusawa, Toshifumi Tada, Shinichiro Nakamura, Ryoichi Narita, Yasushi Uchida, Takehiro Akahane, Masahiko Kondo, Nami Mori, Shintaro Takaki, Keiji Tsuji, Atsunori Kusakabe, Koichiro Furuta, Haruhiko Kobashi, Hirotaka Arai, Michiko Nonogi, Takashi Tamada, Chitomi Hasebe, Namiki Izumi
Publikováno v:
Hepatology Research. 53:61-71
We investigated pretreatment neutrophil-to-lymphocyte ratio (NLR) for predicting survival outcomes of atezolizumab plus bevacizumab therapy for hepatocellular carcinoma (HCC) and determined the predictive ability of combined liver reserve-NLR.This re
Autor:
Nobuharu Tamaki, Toshifumi Tada, Masayuki Kurosaki, Yutaka Yasui, Hironori Ochi, Toshie Mashiba, Azusa Sakamoto, Hiroyuki Marusawa, Ryoichi Narita, Yasushi Uchida, Takehiro Akahane, Masahiko Kondo, Nami Mori, Shintaro Takaki, Keiji Tsuji, Haruhiko Kobashi, Atsunori Kusakabe, Koichiro Furuta, Hirotaka Arai, Michiko Nonogi, Chikara Ogawa, Takashi Sato, Takashi Tamada, Shinichiro Nakamura, Chitomi Hasebe, Kaoru Tsuchiya, Namiki Izumi
Publikováno v:
Investigational new drugs. 40(6)
Alpha-fetoprotein (AFP) response (relative decline in AFP) is associated with imaging response evaluated by response evaluation criteria in solid tumors ver1.1 (RECIST) and survival in treatment for hepatocellular carcinoma (HCC). However, the optima
Autor:
Takashi Sato, Hiroyuki Kimura, Chikara Ogawa, Hirotaka Arai, Nami Mori, Masayuki Kurosaki, Atsunori Kusakabe, Takehiro Akahane, Kouji Joko, Masahiko Kondo, Chitomi Hasebe, Yasushi Ide, Shinichiro Nakamura, Koichiro Furuta, Toshifumi Tada, Akeri Mitsuda, Namiki Izumi, Hitoshi Yagisawa, Yasushi Uchida, Hiroyuki Marusawa, Haruhiko Kobashi, Yuji Kojima, Ryoichi Narita, Keiji Tsuji
Publikováno v:
Journal of Medical Virology. 93:6247-6256
The real-world virological efficacy and safety of interferon-free direct-acting antiviral (DAA) therapy with sofosbuvir (SOF) and velpatasvir (VEL) were assessed in hepatitis C virus (HCV) genotype 1- and 2-infected patients with decompensated cirrho
Autor:
Kaoru Tsuchiya, Masayuki Kurosaki, Azusa Sakamoto, Hiroyuki Marusawa, Yuji Kojima, Chitomi Hasebe, Hirotaka Arai, Kouji Joko, Masahiko Kondo, Keiji Tsuji, Tetsuro Sohda, Hiroyuki Kimura, Chikara Ogawa, Yasushi Uchida, Shuichi Wada, Haruhiko Kobashi, Koichiro Furuta, Masaya Shigeno, Atsunori Kusakabe, Takehiro Akahane, Ryoichi Narita, Hideo Yoshida, Akeri Mitsuda, Yasushi Ide, Tomomichi Matsushita, Namiki Izumi, on behalf of Japanese Red Cross Liver Study Group
Publikováno v:
Cancers, Vol 13, Iss 2608, p 2608 (2021)
Cancers
Volume 13
Issue 11
Cancers
Volume 13
Issue 11
Background: Lenvatinib (LEN) has been approved for patients with unresectable hepatocellular carcinoma (u-HCC) since March 2018 in Japan. We performed a retrospective nationwide multicenter study to clarify the clinical characteristics of LEN in real
Publikováno v:
Anticancer research. 40(9)
Background/aim Hepatic encephalopathy is an adverse event resulting from lenvatinib use in patients with hepatocellular carcinoma (HCC). We analyzed the influence of lenvatinib on portal venous flow velocity (PVV) and serum ammonia concentration. Pat
Autor:
Chikara Ogawa, Hiroyuki Kimura, Tomomichi Matsushita, Keiji Tsuji, Akeri Mitsuda, Kazuhiko Okada, Koichiro Furuta, Chiharu Kawanami, Kouji Joko, Haruhiko Kobashi, Toshie Mashiba, Atsuhiro Morita, Yasushi Ide, Chitomi Hasebe, Hiroaki Okushin, Hiroshi Ito, Tetsuro Sohda, Masayuki Kurosaki, Takashi Satou, Ryo Nakata, Tamada T, Namiki Izumi, Atsunori Kusakabe, Ryoichi Narita, Takehiro Akahane, Masaya Shigeno, Hitoshi Yagisawa, Hironori Ochi
Publikováno v:
Hepatology Research
AIM The present study aimed to determine the real-world efficacy and safety of the non-structural protein (NS)5A inhibitor elbasvir (EBR) combined with the NS3/4A protease inhibitor grazoprevir (GZR) in patients with hepatitis C virus (HCV) genotype